HOME >> BIOLOGY >> NEWS
Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice

A new research study provides evidence that inhibition of cathepsin cysteine proteases may be a viable strategy for treatment of human cancers. Cathepsins are shown to be involved in multiple stages of tumor development in transgenic mouse models of cancer, and pharmacological inhibition of cathepsins impairs tumor growth and progression. The research is published in the May issue of Cancer Cell.

Molecules known as proteases have long been linked with cancer in humans, and the cathepsins are known to be associated with some human malignancies. However, a specific role for cysteine cathepsin proteases in tumor progression has not been examined in detail, and cathepsins as a potential therapeutic target for treatment of cancer have not been previously reported. Dr. Matthew Bogyo from Stanford Medical School and Dr. Douglas Hanahan from the University of California at San Francisco and colleagues demonstrated that cathepsins are elevated in tumors that form in a mouse model of a rare form of pancreatic cancer and a mouse model of cervical cancer. Using specialized chemical reporters that detected enzymatic activity of cathepsins, the researchers revealed that elevated cathepsins activity in tumors was correlated with the formation of tumor blood vessels (angiogenesis), tumor growth, and invasion into normal tissue in these tumor-bearing mice.

Furthermore, treatment of the cancer-prone mice with a pharmacological inhibitor of cysteine cathepsin activity disrupted both early and late stages of tumor development. The effective dose of the inhibitor was not toxic to normal cells, suggesting that it may be a potential candidate for use in the treatment of human cancers.

These results point to cathepsins as a viable target for future anticancer therapeutics. According to Dr. Hanahan, "It is reasonable to suggest that cathepsin inhibitors may show combinatorial benefits with other targeted (and traditional) therapies, which could be revealed in precli
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
17-May-2004


Page: 1 2

Related biology news :

1. Inhibition of insulin-like growth factor receptor-1 as promising anticancer therapeutic
2. Inhibition of Borrelia burgdorferi protein may reduce Lyme disease transmission
3. Inhibition Of A Novel Gene Involved In Phosphorylating Starch In TransgenicPotato Tubers Leads To The Repression Of Cold Induced Sweetening
4. Competitive Inhibition May Enhance Safety Of Minimally Processed Fruits And Vegetables
5. Marijuana ingredient inhibits VEGF pathway required for brain tumor blood vessels
6. The amendment to the law on green Genetic Engineering inhibits innovation and research in Germany
7. Obesity drug inhibits prostate tumor growth
8. Protein inhibits cell growth, may contribute to breast cancer
9. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
10. Aspirin inhibits ovarian cancer growth, lab study finds
11. UIC chemists identify compound that inhibits cell migration

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/4/2019)... , ... October 04, 2019 , ... ... will be held November 10 at the Grand Elysée Hamburg Rothenbaumchaussee in Hamburg. ... Europe again this November,” said Miao Guo, Vice President of Operations and spokesperson ...
(Date:10/3/2019)... ... October 01, 2019 , ... The ... of chemicals, reagents, and medias and to be a more environmentally sustainable evolution ... culmination of years of experience and feedback from the original version we launched ...
(Date:10/3/2019)... ... 02, 2019 , ... Connecticut Innovations (CI), Connecticut’s strategic venture ... innovative, growing companies, today announced that it has closed on a $750,000 investment ... the 2018 VentureClash competition. , The outlay is part of ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... October 02, 2019 , ... Rapid Novor, Inc., ... announce that it has moved into a new, 5000 sqft, purpose-built, state-of-the-art facility. ... facility demonstrates the company's continuous commitment to quality research and service offerings. ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer ... focused on the development of therapies to treat central nervous system (CNS) ...
(Date:9/17/2019)... ... 2019 , ... Catalent, a global leader in clinical supply ... Pacific (APAC) will present at the upcoming 3rd Annual Accelerating Clinical Trials in ... Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney will present “Singapore: APAC’s Clinical ...
(Date:9/17/2019)... (PRWEB) , ... September 16, 2019 , ... ... Nationwide via CNBC on Saturday, September 21st @11:00am ET. Check local listings for ... Pte. Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to ...
Breaking Biology Technology:
Cached News: